ArticleOncotarget2016
Refractory pituitary adenoma: a novel classification for pituitary tumors.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Comprehensive transcriptomic analysis identifies three distinct subtypes of pituitary adenomas: insights into tumor behavior, prognosis, and stem cell characteristics.Journal of translational medicine · 2024Article
- The biological behavior and clinical outcome of pituitary adenoma are affected by the microenvironment.CNS neuroscience & therapeutics · 2024Review
- Diagnosis and Management of Aggressive/Refractory Growth Hormone-Secreting Pituitary Neuroendocrine Tumors.International journal of endocrinology · 2024Review
- Regulation of long noncoding RNAs in the pathogenesis and clinical implications of pituitary adenomas.Immunity, inflammation and disease · 2023Review
- Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need.Pituitary · 2023Review
- Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases.Clinical case reports · 2022Article
- Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments.Frontiers in endocrinology · 2022Article
- The Clinical and Pathological Characteristics of Refractory Pituitary Adenomas: A Single Center Experience.Frontiers in oncology · 2022Article
- Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone.Journal of oncology · 2022Article
- Article
- Diagnosis and treatment of refractory pituitary adenomas: a narrative review.Gland surgery · 2021Review
- Pituitary adenoma or pituitary neuroendocrine tumor: a narrative review of controversy and perspective.Translational cancer research · 2021Review
- Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches.Frontiers in endocrinology · 2021Review
- How to Classify and Define Pituitary Tumors: Recent Advances and Current Controversies.Frontiers in endocrinology · 2021Review
- The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.The Journal of clinical endocrinology and metabolism · 2020Article
- Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.Endocrine pathology · 2020Article
- The Change in Distance Between Bilateral Internal Carotid Arteries in Acromegaly and Its Risk Factors.Frontiers in endocrinology · 2020Article
- Review
- Identification of microRNAs associated with the aggressiveness of prolactin pituitary tumors using bioinformatic analysis.Oncology reports · 2019Article
- Pituitary macroadenoma: Accuracy of apparent diffusion coefficient magnetic resonance imaging in grading tumor aggressiveness.The neuroradiology journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenomas are classified as typical or atypical, invasive or noninvasive, and aggressive or nonaggressive based on pathological features, radiological findings, and clinical behavior. Only pituitary tumors with cerebrospinal and/or systemic metastasis are considered malignant carcinomas. However, some pituitary adenomas with high Ki-67 indexes exhibit aggressive behaviors, such as rapid growth, early and frequent recurrence, and resistance to conventional treatment, even in the absence of metastasis. Novel terminology is needed to define these tumors. Here, we propose the use of the term "refractory pituitary adenoma" to define malignant pituitary tumors exhibiting 1) a high Ki-67 index and rapid growth, 2) early and high frequency of recurrence, 3) resistance to conventional treatments and/or salvage treatment with temozolomide (TMZ), 4) poor prognosis, 5) and a lack of cerebrospinal or systemic metastases. To illustrate the utility of this refractory pituitary adenoma classification and the difficulty in managing disease in these patients, we examined twelve clinical cases. Correctly identifying refractory pituitary adenomas is crucial for improving patient prognoses. Early identification might encourage the early use of aggressive therapeutic strategies to prevent or delay recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.